XIAOYANG MEI: Open Payments
NPI 1871214676 · FLUSHING, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,811 in 85 payments from 10 companies in 2025. Trend: 2023 $3,196 · 2024 $3,939 · 2025 $3,811
Food & beverage: $3,710Education: $101
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $750 |
| Teva Pharmaceuticals USA, Inc. | 16 | $602 |
| ABBVIE INC. | 7 | $595 |
| Alkermes, Inc. | 14 | $525 |
| Axsome Therapeutics, Inc. | 7 | $466 |
| E.R. Squibb & Sons, L.L.C. | 10 | $327 |
| Otsuka America Pharmaceutical, Inc. | 5 | $294 |
| Neurocrine BioSciences, Inc. | 1 | $124 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $113 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
Products named: CAPLYTA, VRAYLAR, Auvelity, UZEDY, COBENFY, REXULTI, ARISTADA, LYBALVI.
Industry payments across NY — which companies pay providers there.
